Browse by UCL people
Group by: Type | Date
Jump to: Article
Number of items: 17.
Article
Alderson, D;
Cunningham, D;
Nankivell, M;
Blazeby, JM;
Griffin, SM;
Crellin, A;
Grabsch, HI;
... Langley, RE; + view all
(2017)
Neoadjuvant cisplatin and fluorouracil versus epirubicin, cisplatin, and capecitabine followed by resection in patients with oesophageal adenocarcinoma (UK MRC OE05): an open-label, randomised phase 3 trial.
The Lancet Oncology
10.1016/S1470-2045(17)30447-3.
(In press).
|
 |
|
Blencowe, NS;
Brown, JM;
Cook, JA;
Metcalfe, C;
Morton, DG;
Nicholl, J;
Sharples, LD;
... Members of the MRC Hub for Trials Methodology Research Network W; + view all
(2015)
Interventions in randomised controlled trials in surgery: issues to consider during trial design.
Trials
, 16
, Article 392. 10.1186/s13063-015-0918-4.
|
|
|
Brueton, V;
Stenning, SP;
Stevenson, F;
Tierney, J;
Rait, G;
(2017)
Best practice guidance for the use of strategies improved retention in randomised trials developed from two consensus workshops.
Journal of Clinical Epidemiology
, 88
pp. 122-132.
10.1016/j.jclinepi.2017.05.010.
|
|
|
Brueton, V;
Tierney, J;
Stenning, S;
Nazareth, I;
Meredith, S;
Harding, S;
Rait, G;
(2011)
Strategies to reduce attrition in randomised trials.
Trials
, 12 Sup
, Article A128. 10.1186/1745-6215-12-S1-A128.
|
 |
|
Brueton, V;
Tierney, JF;
Stenning, S;
Rait, G;
(2017)
Identifying additional studies for a systematic review of retention strategies in randomised controlled trials: making contact with trials units and trial methodologists.
Systematic Reviews
, 6
(1)
, Article 167. 10.1186/s13643-017-0549-9.
|
|
|
Brueton, VC;
Stevenson, F;
Vale, CL;
(2014)
Use of strategies to improve retention in primary care randomised trials: a qualitative study with in-depth interviews.
BMJ Open
, 4
(1)
, Article e003835. 10.1136/bmjopen-2013-003835.
|
|
|
Brueton, VC;
Tierney, J;
Stenning, S;
Harding, S;
Meredith, S;
Nazareth, I;
Rait, G;
(2013)
Strategies to improve retention in randomised trials.
Cochrane Database Syst Rev
, 12
, Article MR000032. 10.1002/14651858.MR000032.pub2.
|
|
|
Brueton, VC;
Tierney, JF;
Stenning, S;
Meredith, S;
Harding, S;
Nazareth, I;
Rait, G;
(2014)
Strategies to improve retention in randomised trials: a Cochrane systematic review and meta-analysis.
BMJ Open
, 4
(2)
, Article e003821. 10.1136/bmjopen-2013-003821.
|
|
|
Cunningham, D;
Stenning, SP;
Smyth, EC;
Okines, AF;
Allum, WH;
Rowley, S;
Stevenson, L;
... Langley, RE; + view all
(2017)
Peri-operative chemotherapy with or without bevacizumab in operable oesophagogastric adenocarcinoma (UK Medical Research Council ST03): primary analysis results of a multicentre, open-label, randomised phase 2-3 trial.
Lancet Oncology
, 18
(3)
pp. 357-370.
10.1016/S1470-2045(17)30043-8.
|
|
|
Diaz Montana, C;
Cragg, W;
Choudhury, R;
Joffe, N;
Sydes, M;
Stenning, S;
(2019)
Implementing monitoring triggers and matching of triggered and control sites in the TEMPER study: A description and evaluation of a triggered monitoring management system.
Trials
, 20
, Article 227. 10.1186/s13063-019-3301-z.
|
|
|
Hale, MD;
Nankivell, M;
Hutchins, GG;
Stenning, SP;
Langley, RE;
Mueller, W;
West, NP;
... Grabsch, HI; + view all
(2016)
Biopsy proportion of tumour predicts pathological tumour response and benefit from chemotherapy in resectable oesophageal carcinoma - results from the UK MRC OE02 trial.
Oncotarget
, 7
(47)
pp. 77565-77575.
10.18632/oncotarget.12723.
|
|
Huddart, RA;
Gabe, R;
Cafferty, FH;
Pollock, P;
White, JD;
Shamash, J;
Cullen, MH;
... National Cancer Research Institute Testis Cancer Clinical Studies Group, .; + view all
(2015)
A randomised phase 2 trial of intensive induction chemotherapy (CBOP/BEP) and standard BEP in poor-prognosis germ cell tumours (MRC TE23, CRUK 05/014, ISRCTN 53643604).
Eur Urol
, 67
(3)
534 - 543.
10.1016/j.eururo.2014.06.034.
|
|
|
Obulkasim, A;
Ylstra, B;
van Essen, HF;
Benner, C;
Stenning, S;
Langley, R;
Allum, W;
... Grabsch, HI; + view all
(2016)
Reduced genomic tumor heterogeneity after neoadjuvant chemotherapy is related to favorable outcome in patients with esophageal adenocarcinoma.
Oncotarget
, 7
(28)
pp. 44084-44095.
10.18632/oncotarget.9857.
|
|
Smyth, E;
Zhang, S;
Cunningham, D;
Wotherspoon, A;
Soong, R;
Peckitt, C;
Valeri, N;
... Tan, P; + view all
(2017)
Pharmacogenetic analysis of the UK MRC MAGIC trial: association of polymorphisms with toxicity and survival in patients treated with perioperative ECF chemotherapy.
Clinical Cancer Research
, 23
(24)
pp. 7543-7549.
10.1158/1078-0432.CCR-16-3142.
|
  |
|
Smyth, EC;
Wotherspoon, A;
Peckitt, C;
Gonzalez, D;
Hulkki-Wilson, S;
Eltahir, Z;
Fassan, M;
... Cunningham, D; + view all
(2017)
Mismatch Repair Deficiency, Microsatellite Instability, and Survival: An Exploratory Analysis of the Medical Research Council Adjuvant Gastric Infusional Chemotherapy (MAGIC) Trial.
JAMA Oncology
, 3
(9)
10.1001/jamaoncol.2016.6762.
|
|
Stenning, SP;
Cragg, WJ;
Joffe, N;
Diaz-Montana, C;
Choudhury, R;
Sydes, MR;
Meredith, S;
(2018)
Triggered or routine site monitoring visits for randomised controlled trials: results of TEMPER, a prospective, matched-pair study.
Clinical Trials
, 15
(6)
pp. 600-609.
10.1177/1740774518793379.
|
 |
|
Tierney, JF;
Pignon, JP;
Gueffyier, F;
Clarke, M;
Askie, L;
Vale, CL;
Burdett, S;
(2015)
How individual participant data meta-analyses have influenced trial design, conduct, and analysis.
Journal of Clinical Epidemiology
, 68
(11)
pp. 1325-1335.
10.1016/j.jclinepi.2015.05.024.
|
